Clinical Case Reports of Injectable Tissue-Engineered Bone for Alveolar Augmentation with Simultaneous Implant Placement

Clinical Case Reports of Injectable Tissue-Engineered Bone for Alveolar Augmentation with Simultaneous Implant Placement
March/April 2005
Minoru Ueda, DDS, PhD/Yoichi Yamada, DDS, PhD/Ryotaro Ozawa, DDS/Yasuhiro Okazaki, DDS, PhD
International Journal of Periodontics and Restorative Dentistry, March/April, Volume 25, Issue 2
You can view the abstract online. A subscription is required to view the full text or it can be purchased online.
This clinical study was undertaken to evaluate the use of tissue-engineered bone, mesenchymal stem cells, platelet-rich plasma, and beta-tricalcium phosphate as grafting materials for maxillary sinus floor augmentation or onlay plasty with simultaneous implant placement in six patients with 3- to 5-mm alveolar crestal bone height. All 20 implants were clinically stable at second-stage surgery and 12 months postloading. A mean increase in mineralized tissue height of 7.3 ¨± 4.6 mm was evident when comparing the pre- and postsurgical radiographs. Injectable tissue-engineered bone provided stable and predictable results in terms of implant success. (Int J Periodontics Restorative Dent 2005;25:129ÇƒÏ137.)